Amgen Inc. $AMGN Shares Acquired by Brookstone Capital Management

Brookstone Capital Management increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.6% in the 1st quarter, HoldingsChannel reports. The firm owned 76,338 shares of the medical research company’s stock after buying an additional 1,929 shares during the quarter. Brookstone Capital Management’s holdings in Amgen were worth $26,859,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lee Johnson Capital Management LLC acquired a new position in Amgen in the first quarter valued at $601,000. Capstone Wealth Management Group LLC acquired a new stake in Amgen in the 4th quarter worth about $207,000. Warren Street Wealth Advisors LLC boosted its stake in Amgen by 390.1% in the 1st quarter. Warren Street Wealth Advisors LLC now owns 20,715 shares of the medical research company’s stock worth $7,289,000 after buying an additional 16,488 shares during the last quarter. Smith Salley Wealth Management grew its holdings in Amgen by 2.9% in the 1st quarter. Smith Salley Wealth Management now owns 11,102 shares of the medical research company’s stock valued at $3,906,000 after buying an additional 316 shares during the period. Finally, Evolve Private Wealth LLC grew its holdings in Amgen by 15.0% in the 1st quarter. Evolve Private Wealth LLC now owns 5,488 shares of the medical research company’s stock valued at $1,931,000 after buying an additional 717 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several research analyst reports. Canaccord Genuity Group initiated coverage on shares of Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price target for the company. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Guggenheim lowered their price objective on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Truist Financial upped their price objective on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Finally, Mizuho increased their target price on Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $354.42.

Amgen Price Performance

AMGN stock opened at $337.60 on Monday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The firm has a market cap of $182.21 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42. The stock has a 50-day simple moving average of $340.71 and a 200-day simple moving average of $345.82.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts predict that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.